SCHEMBL3018856

SCHEMBL3018856

Cc1cc(C)c(-c2csc(N3CCN(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 3/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 1/20 0.38
EPHX2 P34913 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
FABP4 P15090 3/20 0.36
DPP8 Q6V1X1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009044 0.91 LMNA (0.44) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3654660 0.89 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL2999500 0.89 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3001259 0.86 NPSR1 (0.51) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3017577 0.86 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3018508 0.85 AR (0.55) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3014936 0.84 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MAPK1MEN1LMNA
SCHEMBL3012949 0.84 LMNA (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3002220 0.84 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1
SCHEMBL3009218 0.84 SMN1; SMN2 (0.45) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.